Tsewang Tashi, MD
Hematology & Oncology · Salt Lake City, UTNPI 1841440674
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,821 of the $69,124 with a category attached, or 70.6%. 7 manufacturers reported payments, led by Incyte Corporation at 59.5% of the total. Reporting peaked in 2021 at $41,100 and has fallen 93.7% since, to $2,580 in 2025.
Across 21 payments — averaging $3291.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$41K
- Pharmaessentia USA Corporation$13K
- Blueprint Medicines Corporation$10K
- Sanofi US Services Inc.$3K
- CTI Biopharma Corp.$2K
- Jazz Pharmaceuticals Inc.$119
- plus $66 from 1 others
Across 434 payments — averaging $15,167 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Blueprint Medicines Corporation$3.8M
- Pharmaessentia USA Corporation$1.3M
- Sanofi US Services Inc.$771K
- AbbVie$687K
- Incyte Corporation$15K
- Pharmacyclics LLC, An Abbvie Company$1K
What the payments were for
- Consulting fees$19,68828%
- Speaking & faculty fees$48,82171%
- Food & beverage$6151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 2 | $41,100 |
| Pharmaessentia USA Corporation | 6 | $13,131 |
| Blueprint Medicines Corporation | 9 | $10,403 |
| Sanofi US Services Inc. | 1 | $2,580 |
| CTI Biopharma Corp. | 1 | $1,725 |
| Jazz Pharmaceuticals Inc. | 1 | $119 |
| Johnson & Johnson | 1 | $66 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,124 in reported general payments places this provider in the 85th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AyvakitAvapritinib | 37 | $1,381,066 |
| JakafiRuxolitinib Phosphate | 78 | $1,253,914 |
| VonjoPacritinib Citrate | 16 | $327,418 |
| BesremiRopeginterferon Alfa-2b-Njft | 18 | $171,241 |
| OnuregAzacitidine | 12 | $153,558 |
| RevlimidLenalidomide | 11 | $111,862 |
| Ondansetron Hcl | 18 | $3,805 |
| Hydroxyurea | 188 | $3,336 |
| Acyclovir | 72 | $1,128 |
| Anagrelide Hcl | 11 | $891 |
| Allopurinol | 30 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Blueprint Medicines CorporationAyvakit | $10,403 | $1,381,06637 claims |
| Incyte CorporationJakafi | $41,100 | $1,253,91478 claims |
| Pharmaessentia USA CorporationBesremi | $13,131 | $171,24118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in Salt Lake City
- Douglas SborovSalt Lake City$473K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
- Heloisa SoaresSalt Lake City$111K
- Daanish HodaSalt Lake City$80K
- Finn PetersenSalt Lake City$51K
- Anna ChalmersSalt Lake City$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.